A study to evaluate EGFR mutation status of cell free serum DNA and clinical efficacy of afatinib in pretreated non-small cell lung cancer (NSCLC) harboring EGFR mutations.
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2015
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.